Navigating the Landscape of Female Cancers: Recent Discoveries and Treatment Trends

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 1179

Special Issue Editors


E-Mail Website
Guest Editor
Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
Interests: breast cancer; clinical research; translational research; clinical trials; gynecological cancers
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
UOC Oncologia A, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma, Italy
Interests: breast cancer; gynecological cancers; ovarian cancer; cervical cancer; endometrial cancer

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to a Special Issue focused on the latest innovations in the field of female malignancies. Female cancers, encompassing breast, ovarian, cervical, and uterine tumors, among others, present significant challenges in healthcare worldwide. However, significant advancements have been made in the diagnosis and treatment of these diseases over the last few decades.

This Special Issue aims to shed light on recent discoveries and treatment trends in female cancers, providing a comprehensive overview of this topic. By exploring emerging research and clinical practices, we aspire to enhance our current understanding of these diseases.

The subject aligns closely with the scope of Cancers, which prioritizes contributions advancing knowledge in oncology, health, and medical research.

In this Special Issue, we welcome original research articles and reviews addressing various aspects of female cancer. Potential topics for submissions include, but are not limited to, the following:

  • Molecular mechanisms underlying the development and progression of female cancer;
  • Novel diagnostic approaches and biomarkers for early detection;
  • Advances in surgical techniques and minimally invasive interventions;
  • Targeted therapies and immunotherapies for different subtypes of female cancer;
  • Multidisciplinary approaches to comprehensive cancer care;
  • Psychosocial support and quality of life interventions for patients and survivors.

We look forward to receiving your contributions.

Dr. Federica Martorana
Dr. Giacomo Barchiesi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • female malignancies
  • breast cancer
  • gynecological cancer
  • ovarian cancer
  • endometrial cancer
  • cervical cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 1442 KiB  
Article
Superior Survival and Lower Recurrence Outcomes with Breast-Conserving Surgery Compared to Mastectomy Following Neoadjuvant Therapy in 607 Breast Cancer Patients
by Damiano Gentile, Jacopo Canzian, Erika Barbieri, Simone Di Maria Grimaldi, Rita De Sanctis and Corrado Tinterri
Cancers 2025, 17(5), 766; https://doi.org/10.3390/cancers17050766 - 24 Feb 2025
Cited by 1 | Viewed by 791
Abstract
Backgrounds: Neoadjuvant therapy (NAT) is a cornerstone in the management of breast cancer (BC), enabling tumor downstaging and improved surgical options. Methods: This study retrospectively analyzed 607 BC patients treated with NAT and surgery at IRCCS Humanitas Research Hospital, Milan, Italy, to compare [...] Read more.
Backgrounds: Neoadjuvant therapy (NAT) is a cornerstone in the management of breast cancer (BC), enabling tumor downstaging and improved surgical options. Methods: This study retrospectively analyzed 607 BC patients treated with NAT and surgery at IRCCS Humanitas Research Hospital, Milan, Italy, to compare long-term oncologic outcomes of breast-conserving surgery (BCS) versus mastectomy. Patient demographics, tumor characteristics, and treatment details were analyzed using descriptive statistics, logistic regression, and Cox proportional hazards models. Results: Of the 607 patients, 54.7% underwent BCS, and 45.3% had mastectomy. BCS was associated with significantly superior 10-year outcomes compared to mastectomy, including disease-free survival (DFS, 75.2% vs. 71.1%, p = 0.001), distant DFS (75.2% vs. 71.1%, p = 0.001), overall survival (OS, 82.9% vs. 78.1%, p = 0.002), and BC-specific survival (BCSS, 87.7% vs. 83.1%, p = 0.001). Pathologic complete response (pCR) emerged as a protective factor across all endpoints, while mastectomy was independently associated with worse BCSS (HR: 2.068, 95% CI: 1.016–4.210, p = 0.045). Conclusions: Our findings demonstrate the oncologic safety and potential superiority of BCS over mastectomy in NAT-treated BC patients, highlighting the importance of individualized surgical decision-making to optimize survival outcomes. Full article
Show Figures

Figure 1

Back to TopTop